.jpg?format=webp&width=780)
This study aimed to compare the effects of vericiguat versus placebo on left ventricular (LV) structure and function in patients with heart failure with reduced ejection fraction (HFrEF) after 8 months of therapy. The study found that both vericiguat and placebo groups showed significant improvements in LV structure and function. Although there was a tendency for the primary composite endpoint (HF hospitalization or cardiovascular death) to be lower in the vericiguat group, further studies are needed to determine the mechanism of vericiguat's benefits in HFrEF.
Like
Save
Share